What Does AOD9604 Do in Research
Researchers and laboratory professionals must follow all applicable institutional, local, state, and federal regulations governing the handling of research compounds
Pivotal trial result: AOD-9604's Phase 2b trial (536 subjects, 24 weeks) failed its primary endpoint
As featured in Lipotropic + B12 combines amino acids (methionine, inositol, choline) with energy-boosting B12 designed to complement any GLP-1 plan or support metabolism on its own
Decrease dose if: Experiencing consistent side effects (headaches, fatigue, GI disturbance), achieving satisfactory results at current dose with no need for escalation, or cost considerations favor using minimum effective dose
If it does not improve, your provider can evaluate a slight dose reduction, advise reducing caffeine and other stimulants, or discuss alternative appetite suppressants such as Tenuate or Phendimetrazine, which work through different mechanisms and tend to cause less sleep disruption